Individual physiomarkers of levodopa-induced local field potential fluctuations interact with deep brain stimulation in Parkinson’s disease
Objective: We investigated the behavior of LFPs in 57 patients across therapeutic states using a data-driven method to find personalized physiomarkers. Background: The power of…Assessment of Hypomimia in Parkinson’s Disease
Objective: To compare spontaneous facial expression of Happiness as measured by Action Units; AU6 (cheek raise) and AU12 (smile) between individuals with Parkinson’s Disease (PD)…IPX203 (ER CD-LD) super-responders: Description of a patient subpopulation reaping extra benefits in dose-response when converting from IR CD-LD
Objective: To generate quantitative data helping dose optimization when converting Parkinson’s disease (PD) patients from IR CD-LD to IPX203. Background: IPX203 is the first extended-release…Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study
Objective: To investigate the relation between constipation and the onset time of levodopa therapeutic effect in Parkinson's disease (PD). Background: Levodopa therapeutic response depends on…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Nutritional Parameter Changes in Parkinson’s Disease Patients Receiving Continuous Subcutaneous Infusion of Foslevodopa-Foscarbidopa
Objective: This study aims to assess changes in nutritional parameters in patients with Parkinson’s disease (PD) undergoing continuous subcutaneous infusion (CSCI) of foslevodopa-foscarbidopa. Background: Device-aided…Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials
Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…Digital measurement of ocular microtremor in Parkinson’s Disease: Analytical and clinical validation
Objective: This pilot study examined the analytical and clinical validation of OMT measurement via the iTremor ONE device in PwPD. Background: Ocular microtremor (OMT) is…Incidence and Determinants of Nodule formation in continuous subcutaneous Foslevodopa/Foscarbidopa Infusion therapy.
Objective: This study aims to evaluate the incidence of subcutaneous (SC) nodules in Parkinson’s patients treated with continuous 24-hour SC infusion of foslevodopa/foscarbidopa (LDp/CDp) and…Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges
Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 62
- Next Page »